

related land resources plans for the purpose of discounting future benefits and computing costs or otherwise converting benefits and costs to a common time basis.

Dated: December 13, 2001.

Elizabeth Cordova-Harrison,

Deputy Director, Office of Policy.

[FR Doc. 02-925 Filed 1-15-02; 8:45 am]

BILLING CODE 4310-MN-P

INTERNATIONAL TRADE COMMISSION

[USITC SE-02-002]

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: United States International Trade Commission.

TIME AND DATE: January 22, 2002 at 2 p.m.

PLACE: Room 101, 500 E Street SW., Washington, DC 20436, Telephone: (202) 205-2000.

STATUS: Open to the public.

MATTERS TO BE CONSIDERED:

1. *Agenda for future meeting:* None.
2. Minutes.
3. Ratification List.
4. Inv. Nos. 701-TA-409-412 and 731-TA-909 (Final) (Low Enriched Uranium from France, Germany, the Netherlands, and the United Kingdom)—briefing and vote. (The Commission is currently scheduled to transmit its determination and Commissioners' opinions to the Secretary of Commerce on January 28, 2002.)
5. *Outstanding action jackets:* None.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting. Earlier announcement of this meeting was not possible.

Issued: January 10, 2002.

By order of the Commission.

Marilyn R. Abbott,

Acting Secretary.

[FR Doc. 02-1108 Filed 1-11-02; 1:19 pm]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated July 13, 2001, and published in the **Federal Register** on July 23, 2001 (66 FR 38323), Abbott

Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson Road, Whippany, New Jersey 07981, made application to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Dihydromorphine (9145)	I
Hydromorphone (9150)	II

The firm plans to produce bulk product and finished dosage units for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Abbott Laboratories to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Abbott Laboratories to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: January 4, 2002.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 02-935 Filed 1-14-02; 8:45 am]

BILLING CODE 4410-09-M

DEPARTMENT OF JUSTICE

Office of Justice Programs

[OJP(OJP)-1340]

Notice of Intent To Prepare an Environmental Impact Statement (EIS) and Environmental Impact Report (EIR) for the Alameda County Government Center, Including a New Juvenile Justice Facility in the City of Dublin, Alameda County, California

AGENCY: Office of Justice Programs, Justice.

ACTION: Notice of intent (NOI).

SUMMARY: Alameda County (California) proposes to approve a master plan and develop a government center in the East County area, specifically in the City of Dublin, California. The government center is proposed to include a courthouse (15 adult courts), 250,000 square feet of County offices, parking facilities, related site improvements, and a new Juvenile Justice facility with 420 beds, juvenile courts, administration, and associated support facilities (approximately 400,000 square feet total). The Juvenile Justice Facility component of the government center is proposed in response to serious shortcomings in the capability of the existing facility located in San Leandro, California to serve existing and future needs of children in the County. The government center would be developed on a 40-acre County-owned site located at the northern terminus of Hacienda Drive, bounded by Gleason Drive on the south, Arnold Road on the west, Broder Blvd. on the north, and Madigan Avenue on the east. The proposed Alameda County Juvenile Justice project would be funded in part by federal grant monies disbursed by the California Board of Corrections. These funds total \$33,165,000, and are part of the State's allocation from the Violent Offender Incarceration and Truth-in-Sentencing (VOI/TIS) Incentive Grant Program. The County would provide additional funding from bonds, certificates of participation, and the general fund. The total cost for the Juvenile Justice Facility is estimated to be approximately \$177,000,000.

The Department of Justice, the California Board of Corrections and Alameda County are preparing a joint Environmental Impact Statement and Environmental Impact Review (EIS/EIR) document in order to satisfy the requirements of the National Environmental Policy Act (NEPA) and the California Environmental Quality Act (CEQA) concurrently. The U.S. Department of Justice is the lead federal agency under NEPA for the preparation of the EIS/EIR and the California Board of Corrections will be preparing the EIS/EIR under a provision of NEPA that allows an agency of statewide jurisdiction with responsibility for the proposed action (pursuant to the VOI/TIS grant) to prepare an EIS. Alameda County will be the lead agency under CEQA for the preparation of the EIS/EIR for the master plan for the government center as well as the Juvenile Justice Facility.

DATES: Public scoping meetings will be held in the City of Dublin, County of Alameda, California, within thirty days